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Background:  Women  who  use drugs,  irrespective  of  whether  these  are  injected  or not,  are  faced  with
multiple  issues  which  enhance  their  vulnerability  to HIV.
Methods:  In this  commentary,  we  explore  the  HIV risks  and vulnerabilities  of women  who  use  drugs  as
well  as the  interventions  that  have  been  shown  to reduce  their  susceptibility  to  HIV infection.
Results:  Women  who  inject  drugs  are  among  the  most  vulnerable  to HIV  through  both  unsafe  injections
and  unprotected  sex.  They  are  also  among  the  most  hidden  affected  populations,  as  they  are  more  stigma-
tized  than  their  male counterparts.  Many  sell sex  to  ﬁnance  their own  and  their  partner’s  drug  habit  and
often  their  partner  exerts  a signiﬁcant  amount  of control  over  their  sex  work,  condom  use  and  injectionex work
arm reduction
IV
practices.  Women  who  use drugs  all over  the  world  face  many  different  barriers  to  HIV  service  access
including  police  harassment,  judgmental  health  personnel  and a fear  of losing  their children.
Conclusion:  In order  to enable  these  women  to access  life-saving  services  including  needle-syringe  and
condom  programs,  opioid  substitution  therapy  and  HIV  testing  and  treatment,  it is essential  to create  a
conducive  environment  and  provide  tailor-made  services  that  are  adapted  to their  speciﬁc  needs.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDntroduction
Globally, the number of people who inject drugs (PWID) is
pproximately 16 million, of whom 3 million are estimated to be
IV-infected (Mathers et al., 2008). Statistics for females who inject
rugs (FWID) are scarce, but a recently published meta-analysis
Des Jarlais, Feelemyer, Modi, Arasteh, & Hagan, 2012; Des Jarlais,
eelemyer, Modi, Arasteh, Mathers, et al., 2012) of 135 studies with
ata collected between 1982 and 2009, including over 125,000
WID from four continents (excluding Africa and Oceania) had
n overall proportion of 21.5% women, which would correspond
o approximately 3.5 million FWID globally. The analysis revealed
ariation in the female:male odds ratios for HIV prevalence but
verall there was  a modest but signiﬁcantly higher HIV prevalence
mong females with an overall odds ratio of 1.18. FWID had higher
ates of infection than MWID  in Eastern Europe (33.0% vs. 27.9%),
estern Europe (42.8% vs. 40.3%), Latin America (38.5% vs. 34.6%)
nd North America (34.5% vs. 31.3%). A similar review from Central
sia, on data collected between 2002 and 2012, showed that FWID
n Russia, Kazakhstan, Uzbekistan and Tajikistan also had higher
IV prevalence; 10.1% compared to 9.5% among MWID.
∗ Corresponding author. Tel.: +880 28812240.
E-mail address: tasnim@icddrb.org (T. Azim).
ttp://dx.doi.org/10.1016/j.drugpo.2014.09.003
955-3959/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Non-injection drug use e.g. cocaine/crack, heroin,
amphetamine-type stimulants (ATS), that are administered
by snorting, smoking, inhaling, ingesting, and rectal insertion,
are more common worldwide than injection drug use (Shoptaw
et al., 2013). Available global estimates on the numbers of ATS and
cocaine users show high burden (Degenhardt & Hall, 2012) and
ATS use appears to be rising in many countries including some in
South America, East and South East Asia (Dargan & Wood, 2012).
HIV prevalence is also high among persons who use non-injection
drugs (Strathdee & Stockman, 2010) and studies in New York City
have shown that HIV prevalence among injecting and non-injecting
heroin and cocaine users were similar (Des Jarlais et al., 2007).
The principal risk for HIV transmission among non-injection
substance users is from high risk sexual behaviours and both
cocaine and ATS can increase sexual arousal and promote risky
sex (El-Bassel, Shaw, Dasgupta, & Strathdee, 2014a; Shoptaw et al.,
2013; Strathdee & Stockman, 2010). In women, non-injection drug
use has been associated with high risk sexual behaviours including
multiple concurrent partners (Adimora, Schoenbach, Taylor, Khan,
& Schwartz, 2011) and not using condoms (Wechsberg et al., 2010).
Women  who use drugs, irrespective of whether these are
injected or not, are faced with multiple issues which enhance their
vulnerability to HIV; these include concomitant sex work, sexually
transmitted infections (STIs), viral hepatitis, mental health prob-
lems, reproductive health issues, child care, stigma, violence and
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ack of access to health services including for HIV prevention, care
nd treatment. In this commentary, we will provide an overview on
ome of these issues particularly those related to sex work, relation-
hips with intimate partners, STIs, Hepatitis C, stigma and violence,
eproductive health and child care, and availability and access to
IV prevention, care and treatment services.
omen, drug use and sex work
Many women are driven to sell sex to support their own or their
artner’s drug use, which can put them at dual risk of HIV infection:
hrough unsafe sex as well as unsafe injections. Overlap between
ex work and injecting drug use is especially high in parts of East-
rn Europe and Central Asia and is a growing concern in some Latin
merican countries, such as Mexico (El-Bassel et al., 2014a; Morris
t al., 2013). Women  engaging in both the sex trade and use of
llicit drugs are more likely to share needles/syringes and other
njection paraphernalia among themselves and their clients, have
nprotected sex with their clients as well as their intimate partners,
ave higher rates of STIs and they are also more likely to experience
exual violence and incarceration (Azim et al., 2006; Des Jarlais,
eelemyer, Modi, Arasteh, & Hagan, 2012; Des Jarlais, Feelemyer,
odi, Arasteh, Mathers, et al., 2012; El-Bassel, Shaw, Dasgupta, &
trathdee, 2014b). FWID-sex workers (FWID-SW) are more likely
han sex workers who do not use drugs to engage in street-level sex
ork, which is associated with higher levels of violence and high-
isk sex due to a different type of clientele and lack of safe places to
ake clients (Deering et al., 2013). However, sex work can also pro-
ide economic freedom for women. A study in Tanzania revealed
hat females using drugs who also sold sex were more likely to
urchase and use drugs alone than males (Asher, Hahn, Couture,
aher, & Page, 2013; Williams et al., 2007). In general however,
he combination of multiple high-risk behaviours, vulnerabilities
nd discrimination associated with FWID-SW has led to high HIV
revalence among this sub-population. Examples include:
In Central Asia FWID-SW are up to 20 times more likely to acquire
the infection compared to FSW who do not inject drugs (Baral
et al., 2013).
Along the US-Mexican border, HIV prevalence among FWID-SW
is 12.3%, nearly 3 times higher compared to other FSW (Strathdee
et al., 2008).
In Tanzania, 85% of FWID are sex workers and their HIV preva-
lence is 62%, compared to 28% among MWID  (Lambdin et al.,
2013).
In Nepal, over 50% of FWID sell sex and their HIV prevalence
is 33%, compared to 6.3% among MWID  (Ghimire, Suguimoto,
Zamani, Ono-Kihara, & Kihara, 2013).
Since FWID-SW are at high risk of becoming infected with
IV through unprotected sexual intercourse and sharing injection
quipment with intimate partners, clients and peers, this subgroup
eets the criteria for a ‘bridge’ population that is associated with
he transition from concentrated to generalized HIV epidemics (Des
arlais, Feelemyer, Modi, Arasteh, Mathers, et al., 2012).
omen  with intimate partners who inject drugs
FWID are more likely to have MWID  as sex partners (El-Bassel
t al., 2014a). Women’s relationships with their intimate male part-
ers who also use drugs are complicated and dynamic. Generally
hese women work to sustain their own as well as their part-
er’s drug habits. A study on women using drugs and selling sex
n Canada (Shannon et al., 2008) found that men  take control of
omen’s lives through a process of building trust, supplying and Drug Policy 26 (2015) S16–S21 S17
controlling the supply of drugs, gaining control of their sex work
environment and transactions with their clients. Violence – both
physical and sexual – is common and the experience of and the
threat of violence serves to marginalize women further. More-
over, the intimate partner often controls decisions on condom use
(Des Jarlais, Feelemyer, Modi, Arasteh, Mathers, et al., 2012), and
lower rates of condom use have been reported by women who  use
drugs with both clients and their intimate partners (El-Bassel et al.,
2014a).
On the other hand, these relationships are also emotional and
women rely on their intimate partners for companionship as well
as for support to negotiate with clients and law enforcement. A
qualitative study conducted among drug using couples revealed the
complex relationships and the role that emotional considerations
play such that in one case the woman  was initiated into injecting
drugs by her intimate partner on her insistence as she wanted to
be able to better share and understand his life (Simmons, Rajan, &
McMahon, 2012).
Non-drug using women who  are partners of MWID  are also
vulnerable to HIV as unprotected sex with intimate partners is com-
mon. Transmission of HIV to non-injecting wives of MWID  has been
documented in Manipur (Panda et al., 2000). In many cases, the
female partner cannot change risky practices with her partner by
herself, but harm reduction interventions aimed at couples can suc-
cessfully decrease drug use and needle sharing and increase the use
of condoms among drug-using couples (El-Bassel et al., 2014b). In
addition, couple-based approaches often have positive effects on
sexual communication skills and balancing power within the rela-
tionship (Roberts, Mathers, & Degenhardt, 2010). Evidence from
a harm reduction program in Vietnam shows that reaching out
to female partners of MWID  is possible and may be effective in
promoting condom use by the couple (Hammett et al., 2012).
Stigma, discrimination and violence
FWID are more stigmatized and discriminated against than their
male counterparts as reported from several countries (El-Bassel
et al., 2014a). Stigma is prevalent through all strata of society
starting with their own families, friends and neighbours to service
providers and law enforcement. In Bangladesh, a woman who uses
drugs said “when I visit any house they assume I am a thief” (UNODC,
icddrb, & 2010) and a similar opinion was expressed in a study con-
ducted in Georgia – “they (women who use drugs) are liars, big liars
. . .and they are ready to go as far as possible. . . they are ready to
sell themselves. . .” (Otiashvili et al., 2013). In the same study from
Georgia, the attitude of law enforcement was  reﬂected in the state-
ment “Generally the attitude of police towards a drug user is similar
to their attitude towards criminals and not sick people.  . . their atti-
tude towards women is even worse than to men. . .” The views held
by society cause women who  use drugs to suffer from extremely
low esteem, feelings of guilt and self-blame.
Violence is commonly experienced by FWID (Braitstein et al.,
2003) from their intimate partners and in the case of FWID-SW
from their clients as well (Morris et al., 2013). There is a direct cor-
relation between violence and increased HIV vulnerability as data
show that women  who have experienced intimate partner violence
are less likely to use condoms and more likely to share needles,
to have multiple sexual partners and to trade sex (Braitstein et al.,
2003; Gilchrist, Blazquez, & Torrens, 2011). Women also report high
rates of sexual violence from police and law enforcement agencies
and experience high rates of incarceration. In some countries, the
police conﬁscate condoms, sterile injection equipment and other
paraphernalia thus compromising adoption of safe behaviours (El-
Bassel et al., 2014a; UNODC & icddrb, 2010). A sequelae of sexual
violence is post-traumatic stress disorder which is common among
women who use drugs (Braitstein et al., 2003).
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eproductive health care services and child care
Reproductive health services that cater to the needs of women
ho use different types of drugs is essential and these include preg-
ancy related services, birth control, advice on birth spacing and
bortion services. Offering these services is a way to reach out to
omen who use drugs and integrating reproductive health services
ith harm reduction services or vice versa can reduce stigma.
For many women, pregnancy has been the main motivation to
eek drug treatment services, and it was identiﬁed as a ‘turning
oint’ in their lives (Radcliffe, 2011) leading them to sometimes
ecome drug free. In Bangladesh, relapse into drug use following
rug treatment was more common among females than males; and
omen without children to support were more than three times
ikely to relapse (Maehira et al., 2013) which suggests that hav-
ng children can be a strong motivating factor to reduce drugs.
owever, women who are identiﬁed as having a drug use prob-
em, often have their children removed from under their care. In
 study among mothers in opioid pharmacological treatment in
ydney, Australia many of the mothers interviewed said they had
een reported prenatally by a hospital (Taplin & Mattick, 2014).
rug use during pregnancy is criminalized in some states in the
S and in Russia and Ukraine laws allow abortion and termination
f parental rights of drug using women (Pinkham & Malinowska-
empruch, 2008). Such punitive policies can deter pregnant women
nd mothers from entering drug treatment and receiving services
El-Bassel, Terlikbaeva, & Pinkham, 2010).
Health care providers are often not trained to deal with the
nique needs of women who use drugs and can have a hostile atti-
ude towards the women which poses a signiﬁcant deterrent for
omen to seek treatment (Simpson & McNulty, 2008). There is a
eed to recognise that pregnant women who use drugs and who
eek help for their drug use are often motivated to act in the inter-
sts of their children and health care providers should be trained
o offer them a range of opportunities both antenatally and postna-
ally (Marsh, D‘Aunno, & Smith, 2000; Radcliffe, 2011). It is also an
pportunity for providing prevention from mother to child trans-
ission (PMTCT) of HIV so that children are born HIV free (El-Bassel
t al., 2014a). More needs to be done to support these women
round the issues that impact on their ability to parent and where
hildren are under care of others, having contact with their chil-
ren that is known to be helpful to all involved (Taplin & Mattick,
014).
o-infections and co-morbidities and the need for
ppropriate services
Persons who use drugs can often experience multiple infec-
ions and other conditions such as mental disorders. Diagnosis,
vailability of treatment and access for these conditions vary
epending on the context including geography and gender. Exam-
les of infections include STIs, viral hepatitis, and tuberculosis. STIs
re not uncommon among women who use drugs (Azim et al.,
006; Guerrero & Cederbaum, 2011). Herpes simplex type 2 was
ound at particularly high levels in PWID in the US as well as the
arcinogenic strains of human papilloma virus (HPV16 and 18)
Belani et al., 2012). However, services provided for STI diagnosis
nd management falls short of the need (Guerrero & Cederbaum,
011). Hepatitis C virus (HCV) infection is common among PWID
Bruggmann & Grebeley, 2014; Nelson et al., 2011) and treatment
s not widely available (Altice, Kamarulzaman, Soriano, Schechter, Friedland, 2010). An analysis of data among PWID attending
he Australian Needle and Syringe Programs between 1999 and
011where treatment was  available for HCV, showed that uptake
f treatment was signiﬁcantly lower in FWID than MWID (Iversen Drug Policy 26 (2015) S16–S21
et al., 2014). Tuberculosis is also prevalent among PWID especially
among those who  are HIV positive (Belani et al., 2012) but gender
disaggregated data are not available.
People who  use drugs are at higher risk of depression, anxiety,
and severe mental illness, including attempted suicide compared
with those who do not use illicit drugs (Belani et al., 2012;
Degenhardt & Hall, 2012). The prevalence of depression among
heroin smokers has been found to be higher in females than males
(Sordo et al., 2012).
Addressing these multiple co-infections and co-morbidities is
best done in an integrated manner. In the UK,  a national mental
health strategy emphasises the need for integrated care to enable
diagnosis and management of the co-morbidities of drug use and
mental illness in women  (Simpson & McNulty, 2008). Similarly in
the US, the guidance proposed by the Centers of Disease Control and
Prevention recommends that uptake of services will be enhanced
if they are provided in a single site (Belani et al., 2012). The guid-
ance also recommends that health care professionals are trained to
recognise, manage and treat conditions in a culturally and gender
sensitive manner.
Behavioural and structural interventions
Several interventions designed speciﬁcally for women using
drugs have been implemented involving drug treatment along
with education, counselling, reproductive health services, child
care, female only drop in centres in different countries including
Bangladesh, Canada, Russia, Ukraine, US (Pinkham, Stoicescu, &
Myers, 2012; UNODC, 2013). Most of these services have not been
validated by formal research but reports from the programs sug-
gest that they have been successful in increasing the number of
women accessing health services. However a few studies have been
conducted and two  examples are provided below:
A randomized trial was  conducted in the US to test effective-
ness of HIV/STI safer sex skills building (SSB) groups for women
in community drug treatment vs. standard HIV/STI Education (HE)
(Tross et al., 2008). The SSB consisted of ﬁve 90-min group sessions
using problem-solving and skills rehearsal to increase HIV/STI risk
awareness, condom use and partner negotiation skills. In HE, one
60-min group covered HIV/STI disease, testing, treatment, and pre-
vention information. The SSB resulted in signiﬁcant improvement
in safer sex practices that were maintained over a longer duration
compared to the HE group.
Behavioural interventions combining motivational techniques
were used to assess whether both safer sex and safer injection
taking practices could be promoted among FWID-SW. Two brief
30-min theory-based interventions based on motivational inter-
viewing were found to reduce both injection and sexual risks
among FWID-SW in two  Mexico-US border cities (Strathdee et al.,
2013). The results showed that FWID-SW can reduce sexual risks if
given the right information and negotiation skills. The injection risk
intervention has value in settings with sub-optimal syringe access
but sterile needle-syringe coverage is essential.
A review on behavioural strategies to reduce injecting and sex-
ual risk suggested that brief, standard, educational approaches may
be more cost-effective than widespread use of formal multisession
psychosocial interventions (Meader, Li, Des Jarlais, & Pilling, 2010).
HIV prevention and harm reduction for women who  use
drugsComprehensive packages for HIV prevention in people who use
drugs as recommended by WHO, UNODC and UNAIDS consists
of nine interventions including oral substitution therapy (OST),
needle and syringe programs (NSPs), condoms and HIV testing
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nd treatment (World Health Organization, 2012). Modelling has
hown that simultaneous scale-up of NSPs, HIV testing, OST and
ntiretroviral treatment (ART) can reduce HIV incidence by up to
3% (Degenhardt et al., 2010). But despite the global commitment
f universal access to HIV prevention, testing, treatment and care
eople who use drugs, especially women, are less likely to uti-
ize these services (Malta, Ralil da Costa, & Bastos, 2014). Women
ho use drugs, just like any other person, want to lead healthy
ives, but they are constrained in accessing services by social and
tructural factors including prejudiced health professionals, lack of
ender appropriate services, costs, unsafe/indiscrete locations, fear
f losing their children and partner violence (Olsen, Banwell, Dance,
 Maher, 2012; Roberts et al., 2010). Structural interventions are
herefore required to ensure beneﬁts from the combination of ser-
ices recommended (Strathdee et al., 2010).
With the recent interest and attention on biomedical preven-
ion, female condoms have dropped out of the radar as an effective
revention technology. Female condoms, similar to male condoms,
re not only effective for HIV prevention but also for birth con-
rol. Unfortunately they have not been used widely although it
as found to be acceptable to many women and one of the fac-
ors that prevented the wide scale use of female condoms was  cost
ut studies in Brazil, South Africa, and Washington, DC suggest that
xpanded distribution would be cost effective in preventing HIV
nfection in those settings (Adimora et al., 2013). Another factor is
ack of knowledge on how to use female condoms on the part of
ealthcare providers who therefore do not promote this method
Mantell et al., 2011).
It is recommended that people who use drugs be tested for
IV annually (McNairy & El-Sadr, 2014) to enable early detection
f infection. For this to happen it is recognised that HIV testing
nd counselling needs to be reconceptualised, simpliﬁed and nor-
alised (Sidibé, Zuniga, & Montaner, 2014). The development of
uick and reliable tests which can be used outside traditional health
acilities has the potential to greatly increase coverage among FWID
nd other populations who are reluctant to visit health care facili-
ies. Community-based testing has been successfully used in both
igh- and low resource settings, and reached uptakes as high as
9.7% among FSW and 94.5% for PWID, with good linkage to treat-
ent and care (Suthar et al., 2013). Outreach services for FWID
hould be expanded to include point-of-care testing, with referral
o appropriate care for those who are positive.
Pre-exposure prophylaxis (PrEP) with antiretroviral drugs used
y uninfected people can protect them from becoming infected.
aily oral tenofovir has recently been shown to halve the number of
ew HIV-infections among PWID in Bangkok over a ﬁve year period,
ith even more pronounced effects (79%) in FWID due to bet-
er adherence (Choopanya et al., 2013). However, there are many
ssues related to PrEP which need to be considered before PrEP can
ecome a reality especially among marginalised and stigmatised
opulations such as PWID and more so among women who  use
rugs. These issues have been presented in a consensus statement
ormulated by a group of organizations and advocates, the Com-
unity Consensus Statement on the Use of Antiretroviral Therapy
n Preventing HIV Transmission, that outlines a set of principles for
he provision of PrEP (available at www.hivt4p.org) (Cairns, Baker,
edes, Zakowicz, & West, 2014). A key issue highlighted in the
onsensus statement is the involvement of communities in con-
ucting research and providing services and within a human rights
ramework.
It is now well established that effective ART minimizes the risk
f further transmission of HIV by greatly reducing the number of
ree virus in the body. And for this reason WHO  in its June 2013ART
uidelines recommends the use of treatment as a prevention
ethod for people who  are at increased risk of transmitting the
nfection, such as PWID and sex workers, as well as for couples Drug Policy 26 (2015) S16–S21 S19
where only one partner is infected. However, PWID are less likely
than other patients with HIV infection to receive ART (Wolfe,
Carrieri, & Shepard, 2010). Adherence to the ART regimen has been
a key concern in people who  use drugs (Altice et al., 2010; Binford,
Kahana, & Altice, 2012). However, studies have shown that adher-
ence to ART among HIV positive PWID is possible and a recent
review of the international literature demonstrated that greater
adherence can be achieved if ART is provided in structured settings
such as with OST (Malta, Magnanini, Strathdee, & Bastos, 2010).
Thus the continuum of care and treatment for women who use
drugs starting from early detection of HIV through acceptable test-
ing strategies, using ART for prevention and treatment and assuring
adherence requires a multifaceted approach with involvement of
the communities for best results.
Conclusions
Women  who inject drugs often have higher rates of HIV
than males using drugs which is because of the dual risk from
unsafe injection practices and unprotected sex. Sex work is
common among FWID, and FWID-SW are more likely to share nee-
dles/syringes and other injection paraphernalia, have unprotected
sex with their clients as well as their intimate partners and have
higher rates of STIs. For this reason, harm reduction should be
included in all interventions for sex workers and services for safer
sex should be part of all harm reduction programs for women who
use drugs. The comprehensive package of harm reduction services
needs to be made available with inclusion of reproductive health
services.
Women  are often reliant on their male partners for buying drugs
and may  require help in injecting. In the case of FWID-SW, men
often control their clients. Such reliance on men, allow men con-
trol over their lives. Interventions must focus on strengthening the
ability of women  to achieve autonomy over HIV risk reduction prac-
tices, including freedom from pimps and police harassment and
availability of safe places to take clients. Targeted interventions to
empower women so that they are better able to seek and utilize ser-
vices work and need to be adopted widely. Female condoms need
to be made available and costs reduced.
As FWID are more stigmatized than their male counterparts,
this can be a barrier for seeking services whether this is for harm
reduction or drug treatment. Therefore, all health care personnel
should be trained to provide a supportive, culturally sensitive and
non-judgmental environment. Integration of harm reduction with
reproductive health services as well as other services for the man-
agement of co-infections and co-morbidities must be considered.
Child care service for women  who  use drugs can help promote
adoption of safer behaviours and laws allowing forced abortions
or removal of children from the care of mothers who take drugs
must be removed. PMTCT services for pregnant drug using women
must be made widely available.
Women  who  are sex partners of MWID  but do not inject drugs
themselves are vulnerable to HIV infection through their partners
risk behaviours as condom use with intimate partners is very low.
Couple-based interventions are effective for decreasing drug use
and HIV risk behaviours. In addition, biomedical interventions such
as ART and PrEP should be provided to women who  use drugs and
are affected and infected by HIV. More research on PrEP in women
who use drugs are warranted to understand how to overcome bar-
riers and special efforts that allow adherence to ART need to be
undertaken with the involvement of communities. Furthermore,
there is need for greater access to HIV testing that is acceptable to
women in different settings.
The contents and conclusions of this paper reﬂect a broad con-
sensus among social and clinical scientists participating in a UNODC
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cientiﬁc Consultation on HIV/AIDS (UNODC, Scientiﬁc Statement,
arch 11, 2014).
Conclusion Statements:
- Women who inject drugs often have higher rates of HIV than
males using drugs. This is because of the dual risk from
unsafe injection practices and unprotected sex. Since sex
work is common among females who inject drugs (FWID),
harm reduction should be included in all interventions for sex
workers and safer sex messages should be part of all harm
reduction programs for FWID.
- Women who use drugs and sell sex are more likely to
share needles/syringes and other injection paraphernalia,
have unprotected sex with their clients as well as their inti-
mate partners, have higher rates of STIs and they are also
more likely to experience sexual and physical violence and
incarceration.
- Women are often reliant on their male partners for buying
drugs and they also require help in injecting. In the case of
those women who also trade sex, men  often control their
clients. Such reliance on men, allow men  control over their
lives. Interventions must focus on strengthening the ability
of women to achieve autonomy over HIV risk reduction prac-
tices, including freedom from pimps and police harassment
and availability of safe places to take clients.
- Women who  use drugs are more stigmatized than their male
counterparts and this can be a barrier for seeking services
whether this is for harm reduction or drug treatment. Tar-
geted interventions to empower women so that they are
better able to seek and utilize services work and need to
be adopted widely. In addition, training of health and social
workers to recognize signs of injecting drug use and offer
referral to appropriate services can increase service uptake.
- Services must be tailored for the needs of female drug users
and include specialized care and support for pregnant women
and women with children. This can be achieved through
mobile services, home visits or female-only drop-in centres.
All personnel should be trained to provide a supportive,
culturally sensitive and non-judgmental environment. Inte-
gration of harm reduction with reproductive health services
may  be considered.
- Women who are sex partners of MWID  but do not inject
drugs themselves are vulnerable to HIV infection through
their partners risk behaviours as condom use with intimate
partners is very low. Couple-based interventions are effective
for decreasing drug use and HIV risk behaviours.
- Interventions targeted to women to enable them to seek ser-
vices, receive services that are non-judgemental and tailored
to their speciﬁc needs work should be initiated and expanded.
In addition, biomedical interventions such as ART and PreP
are highly effective in reducing the incidence of HIV and
should be provided to women who use drugs and are affected
and infected by HIV.
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